logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Leinco Technologies Inc. completes acquisition of QED Biosciences to expand antibody capabilities

Sep 03, 2024•over 1 year ago

Acquiring Company

Leinco Technologies

Acquired Company

QED Biosciences

FentonSan DiegoManufacturingBiotechnologyHealth Care

Description

Leinco Technologies has acquired QED Biosciences, a leading provider of antibodies, kits, and recombinant proteins and antigens. This strategic acquisition will enable Leinco to expand its portfolio of antibody capabilities used globally for research and diagnostics, targeting the IVD and research sectors.

Company Information

Company

Leinco Technologies

Location

Fenton, Missouri, United States

About

Established in 1992, Leinco Technologies is a specialty manufacturer of early discovery research products, including antibodies, recombinant proteins, ELISA kits, and other life sciences products. Additionally, the company offers a full suite of custom development and manufacturing services and serves leading drug discovery and in vitro diagnostic companies around the world. Headquartered outside of St. Louis, Missouri, Leinco operates out of a 27,000 square foot facility with significant laboratory space to service all customer and regulatory requirements.

Related People

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed